While administration of LTβR agonist Abs combined with Treg depletion resulted in development of HEV networks in all tumors, this was accompanied by only a very modest improvement in tumor control and T-cell infiltration (Fig. 7A–C). The gene discussed is LTBR; the disease is neoplasm.